• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尽管有疾病修正疗法,但 B 细胞谱系的持续失调仍会促进多发性硬化症的活动。

Continued dysregulation of the B cell lineage promotes multiple sclerosis activity despite disease modifying therapies.

机构信息

Neurologia y Neuroimagen, Instituto Neurologico de Colombia (INDEC), Medellin, Antioquia, Colombia.

Spine & Brain Institute, Ascension St. Vincent's Riverside Hospital, Jacksonville, FL, 32204, USA.

出版信息

F1000Res. 2023 Aug 1;10:1305. doi: 10.12688/f1000research.74506.2. eCollection 2021.

DOI:10.12688/f1000research.74506.2
PMID:37655229
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10467621/
Abstract

A clear understanding of the origin and role of the different subtypes of the B cell lineage involved in the activity or remission of multiple sclerosis (MS) is important for the treatment and follow-up of patients living with this disease. B cells, however, are dynamic and can play an anti-inflammatory or pro-inflammatory role, depending on their milieu. Depletion of B cells has been effective in controlling the progression of MS, but it can have adverse side effects. A better understanding of the role of the B cell subtypes, through the use of surface biomarkers of cellular activity with special attention to the function of memory and other regulatory B cells (Bregs), will be necessary in order to offer specific treatments without inducing undesirable effects.

摘要

清楚了解参与多发性硬化症(MS)活动或缓解的不同 B 细胞谱系亚型的起源和作用,对于患有这种疾病的患者的治疗和随访非常重要。然而,B 细胞是动态的,可以根据其环境发挥抗炎或促炎作用。B 细胞耗竭已被证明可有效控制 MS 的进展,但它可能会产生不良的副作用。为了提供无不良反应的特定治疗方法,有必要通过使用细胞活性的表面生物标志物,特别关注记忆 B 细胞和其他调节性 B 细胞(Bregs)的功能,更好地了解 B 细胞亚型的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5e/10513383/814d78164857/f1000research-10-153768-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5e/10513383/814d78164857/f1000research-10-153768-g0000.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca5e/10513383/814d78164857/f1000research-10-153768-g0000.jpg

相似文献

1
Continued dysregulation of the B cell lineage promotes multiple sclerosis activity despite disease modifying therapies.尽管有疾病修正疗法,但 B 细胞谱系的持续失调仍会促进多发性硬化症的活动。
F1000Res. 2023 Aug 1;10:1305. doi: 10.12688/f1000research.74506.2. eCollection 2021.
2
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
3
Short-Term Memory Impairment短期记忆障碍
4
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
5
Assessing the comparative effects of interventions in COPD: a tutorial on network meta-analysis for clinicians.评估慢性阻塞性肺疾病干预措施的比较效果:面向临床医生的网状Meta分析教程
Respir Res. 2024 Dec 21;25(1):438. doi: 10.1186/s12931-024-03056-x.
6
Rituximab for relapsing-remitting multiple sclerosis.利妥昔单抗用于复发缓解型多发性硬化症。
Cochrane Database Syst Rev. 2013 Dec 6;2013(12):CD009130. doi: 10.1002/14651858.CD009130.pub3.
7
Spinal Muscular Atrophy脊髓性肌萎缩症
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.中枢神经系统罕见的非多发性硬化脱髓鞘疾病
Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8.
10
Memory rehabilitation for people with multiple sclerosis.针对多发性硬化症患者的记忆康复治疗。
Cochrane Database Syst Rev. 2016 Mar 23;3:CD008754. doi: 10.1002/14651858.CD008754.pub3.

本文引用的文献

1
Biomarkers in autoimmune diseases of the central nervous system.中枢神经系统自身免疫性疾病的生物标志物。
Front Immunol. 2023 Apr 5;14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023.
2
B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis.多发性硬化症患者自体造血干细胞移植后的 B 细胞重建。
Neurol Neuroimmunol Neuroinflamm. 2022 Oct 13;9(6). doi: 10.1212/NXI.0000000000200027. Print 2022 Nov.
3
No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial).
鞘内注射利妥昔单抗对进展性多发性硬化症无早期疗效(EFFRITE临床试验)。
Mult Scler Int. 2021 Mar 8;2021:8813498. doi: 10.1155/2021/8813498. eCollection 2021.
4
Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?多发性硬化症中的异位淋巴滤泡:疾病控制中心?
Front Neurol. 2020 Dec 8;11:607766. doi: 10.3389/fneur.2020.607766. eCollection 2020.
5
Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.芬戈莫德和那他珠单抗对多发性硬化症患者 B 细胞库的差异影响。
Neurotherapeutics. 2021 Jan;18(1):364-377. doi: 10.1007/s13311-020-00975-7. Epub 2020 Nov 30.
6
B Cells in Multiple Sclerosis and Virus-Induced Neuroinflammation.多发性硬化症和病毒诱导的神经炎症中的B细胞。
Front Neurol. 2020 Nov 3;11:591894. doi: 10.3389/fneur.2020.591894. eCollection 2020.
7
Should I stop or should I go on? Disease modifying therapy after the first clinical episode of multiple sclerosis.我应该停止还是继续?多发性硬化首次临床发作后的疾病修正治疗。
J Neurol. 2021 Apr;268(4):1247-1253. doi: 10.1007/s00415-020-10074-4. Epub 2020 Sep 14.
8
Defective CD19+CD24CD38 transitional B-cell function in patients with relapsing-remitting MS.复发缓解型多发性硬化症患者中存在缺陷的 CD19+CD24-CD38 过渡性 B 细胞功能。
Mult Scler. 2021 Jul;27(8):1187-1197. doi: 10.1177/1352458520951536. Epub 2020 Sep 14.
9
Serious safety events in rituximab-treated multiple sclerosis and related disorders.利妥昔单抗治疗多发性硬化症及相关疾病的严重安全事件。
Ann Clin Transl Neurol. 2020 Sep;7(9):1477-1487. doi: 10.1002/acn3.51136. Epub 2020 Aug 6.
10
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.抑制布鲁顿酪氨酸激酶可干扰中枢神经系统炎症性脱髓鞘疾病中的致病性 B 细胞发育。
Acta Neuropathol. 2020 Oct;140(4):535-548. doi: 10.1007/s00401-020-02204-z. Epub 2020 Aug 6.